| Summary points: | A 57-year-old female and a 62-year-old female, both diagnosed with adenocarcinoma with liver cirrhosis, receive alternate-day administration of gefitinib. Computed tomography, laboratory tests, hematology, and histopathology are described. The authors discuss the potential for reduced doses of gefitinib for patients with liver dysfunction. |
Gefitinib for Non-Small Cell Lung Cancer Patients with Liver Cirrhosis
